Rafferty Asset Management, LLC Rapt Therapeutics, Inc. Transaction History

Rafferty Asset Management, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$11.28 - $25.46 $74,515 - $168,188	-6,606 Reduced 6.73%	91,553 $2.28 Million
Q3 2023 Nov 13, 2023	SELL	$16.34 - $24.66 $476,278 - $718,789	-29,148 Reduced 22.9%	98,159 $1.63 Million
Q2 2023 Aug 11, 2023	BUY	$16.06 - $21.61 $254,824 - $342,885	15,867 Added 14.24%	127,307 $2.38 Million
Q1 2023 May 11, 2023	SELL	$17.19 - $30.8 $597,008 - $1.07 Million	-34,730 Reduced 23.76%	111,440 $2.04 Million
Q4 2022 Feb 13, 2023	BUY	$16.28 - $24.6 $1.22 Million - $1.84 Million	74,960 Added 105.27%	146,170 $2.89 Million
Q3 2022 Nov 14, 2022	BUY	$17.96 - $30.46 $1.28 Million - $2.17 Million	71,210 New	71,210 $1.71 Million
Q2 2022 Aug 12, 2022	SELL	$10.26 - $23.59 $859,100 - $1.98 Million	-83,733 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$17.02 - $40.22 $6,808 - $16,088	-400 Reduced 0.48%	83,733 $1.84 Million
Q4 2021 Feb 10, 2022	BUY	$29.5 - $39.5 $2.48 Million - $3.32 Million	84,133 New	84,133 $3.09 Million

105

27.1M

26.7K

2.4K

Ticker RAPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,656,600
Market Cap $35.6M
Description
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that se...

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Rafferty Asset Management, LLC with notifications on news.